AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03177161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Patient Reported Health Status Questions
Description: The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
Study NCT01901835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Participate in media diversion with humorous and non-humorous movies
Study NCT01901835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT01901835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01451801 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Twinrix
Description: A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin.
Study NCT04519996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Internal Jugular Vein Collapsibility Index measurment
Description: Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position.
Study NCT04519996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Inferior Vena Cava Collapsibility Index measurment
Description: Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100.
Study NCT03370770 — intervention group
Intervention type: DRUG
Intervention: Afatinib
Description: GILOTRIF, GIOTRIF, XOVOLTIB
Study NCT03370770 — intervention group
Intervention type: DRUG
Intervention: Osimertinib
Description: on T790M resistance mutation was developed
Study NCT03135145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lite Run Gait Trainer
Description: Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient.
Study NCT03135145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Treatments
Description: The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
Study NCT00179959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite (bleach) baths
Description: Sodium hypochlorite (bleach) baths twice weekly for 3 months
Study NCT00179959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
Study NCT00179959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water baths twice weekly for three months
Study NCT00179959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum Ointment
Description: Intranasal petrolatum ointment twice daily for five days
Study NCT00793767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: bolus of 400 IU/kg
Study NCT00793767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: i.v
Study NCT01552681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept
Description: Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
Study NCT01552681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
Study NCT04363333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home Sleep Apnea Testing or In-hospital Polysomnography
Description: Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
Study NCT00627237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Start
Description: Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
Study NCT00627237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist
Description: Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
Study NCT03871894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)
Description: Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
Study NCT03871894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)
Description: Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
Study NCT03871894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard and fixed nutritional intervention till patient in ICU
Description: Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
Study NCT03871894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard and fixed nutritional intervention till patient in ICU
Description: Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
Study NCT02800460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fMRI-3T
Description: fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (single prime, single boost)
Description: Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (Double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (double prime, single boost)
Description: Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study NCT00814385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflunov (No prime, single boost)
Description: No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage therapy
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain therapy
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT01029405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: Ointment B, 2% or 0.5% applied once or twice daily
Study NCT01029405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment B Vehicle applied once or twice daily
Study NCT03976180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stadard low-flow oxygen
Description: In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
Study NCT03976180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with low FiO2 (21%-30%)
Description: HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
Study NCT02170311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Study NCT02318758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: sustained release oral treprostinil
Study NCT02318758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol
Description: Absolut 100 vodka
Study NCT01350089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without alcohol, caffeine, energy drink)
Description: (carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
Study NCT01350089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 1 (with alcohol; without caffeine and energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
Study NCT01350089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 2 (with alcohol and caffeine; without energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
Study NCT01350089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 3 (with alcohol and energy drink)
Description: Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
Study NCT01773655 — intervention group
Intervention type: OTHER
Intervention: tumor specimens
Description: All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome.
Study NCT01596257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant
Study NCT01596257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant
Study NCT01596257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Study NCT01596257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Study NCT04049019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine collection through a collecting device (Uridome®) for maximum 1 week
Description: The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night.
Study NCT01950637 — intervention group
Intervention type: BEHAVIORAL
Intervention: No treatment given
Description: Completion of 90-item online questionnaire.
Study NCT03976180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with intermediate FiO2 (50%)
Description: In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
Study NCT03976180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO with high FiO2 (100%)
Description: In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
Study NCT03253471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-611
Description: AL-611 tablets
Study NCT03253471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match AL-611
Study NCT02643056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: IV administration every 2 weeks
Study NCT02592642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Program, Workbook, Video, Pedometer
Description: Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
Study NCT02592642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructional Workbook, Video, and Pedometer
Description: Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
Study NCT02592642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Para-spinal TENS
Description: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
Study NCT02592642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Para-spinal Placebo TENS
Description: Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
Study NCT02592642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Spinal Stenosis Belt
Description: Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
Study NCT02592642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Spinal Stenosis Belt
Description: Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
Study NCT01073371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine